FDA staff take neutral stance on Moderna, J&J boosters ahead of two-day meeting
Advisers are discussing an authorization of Moderna’s booster on Thursday, with a vote on recommendations to the FDA expected this afternoon.
New York Attorney General sends cease and desist to hospital allegedly using unlicensed temporary staffing agency amid strike
The letter asks the agency to stop providing services to Catholic Health’s Mercy Hospital in Buffalo either for employment or security, and to make sure replacement workers do not interfere with the rights of picketers.
Abbott, Dexcom could benefit from CGM use jump among Type 2 diabetes patients: report
The population could drive the next wave of demand for devices to track and control diabetes, Jefferies analysts predict, following a recent CMS coverage change that rolled back restrictions to CGM access.
Hospitals still spending more on PPE, labor as result of COVID-19
Hospitals spent more than $3 billion on personal protective equipment since the start of the pandemic, though costs have steadily declined since peaking last year, according to a Premier analysis.
CommonSpirit CEO Lloyd Dean to retire next year
The announcement sets off a search for his successor as the organization heads into its third full fiscal year.
FDA breakthrough nods go to liquid biopsies for Alzheimer’s, cancer drug response
The agency gave the designation to Quanterix’s blood test, which has the potential to aid evaluation of people who present with cognitive impairment, and Nonagen Bioscience’s non-invasive bladder cancer test.
Best Buy’s latest health acquisition builds on plan to expand at-home care
It’s the third healthcare buy for the Minneapolis-based consumer electronics giant, as the company looks to capitalize on trends like the aging population and rising demand for lower-cost care.
Tenet’s surgery center buying spree continues as it signs deal for 9 more facilities
The deal with Compass Surgical Partners builds on the hospital operator’s long-term strategy of expanding that line.
AstraZeneca builds case for long-acting COVID-19 drug, but is it too late?
The British drugmaker could soon become the first with both a marketed vaccine and treatment for COVID-19, a notable achievement. Yet competition has blunted the potential impact of each of them.
‘A quiet suffering’: Primary care struggles with COVID-19 strain, telemedicine rollbacks
Despite broad bipartisan support for telehealth in Washington, the return of restrictions — even nominal ones — threaten the viability of virtual services offered by cash-strapped primary care offices, a new survey finds.